JP2015134813A5 - - Google Patents

Download PDF

Info

Publication number
JP2015134813A5
JP2015134813A5 JP2015075105A JP2015075105A JP2015134813A5 JP 2015134813 A5 JP2015134813 A5 JP 2015134813A5 JP 2015075105 A JP2015075105 A JP 2015075105A JP 2015075105 A JP2015075105 A JP 2015075105A JP 2015134813 A5 JP2015134813 A5 JP 2015134813A5
Authority
JP
Japan
Prior art keywords
core
positive
cells
microorganism
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015075105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015134813A (ja
Filing date
Publication date
Priority claimed from EP06090209A external-priority patent/EP1920782A1/en
Application filed filed Critical
Publication of JP2015134813A publication Critical patent/JP2015134813A/ja
Publication of JP2015134813A5 publication Critical patent/JP2015134813A5/ja
Withdrawn legal-status Critical Current

Links

JP2015075105A 2006-11-10 2015-04-01 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分 Withdrawn JP2015134813A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06090209A EP1920782A1 (en) 2006-11-10 2006-11-10 Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
EP06090209.5 2006-11-10
EP06090208.7A EP1920781B1 (en) 2006-11-10 2006-11-10 Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
EP06090208.7 2006-11-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009535633A Division JP2010508834A (ja) 2006-11-10 2007-11-12 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分

Publications (2)

Publication Number Publication Date
JP2015134813A JP2015134813A (ja) 2015-07-27
JP2015134813A5 true JP2015134813A5 (https=) 2015-12-03

Family

ID=39200183

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009535632A Expired - Fee Related JP5771355B2 (ja) 2006-11-10 2007-11-12 微生物およびその部分が誘導する炭水化物特異的細胞性免疫
JP2009535633A Withdrawn JP2010508834A (ja) 2006-11-10 2007-11-12 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分
JP2015075105A Withdrawn JP2015134813A (ja) 2006-11-10 2015-04-01 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分
JP2015074801A Withdrawn JP2015133979A (ja) 2006-11-10 2015-04-01 微生物およびその部分が誘導する炭水化物特異的細胞性免疫

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009535632A Expired - Fee Related JP5771355B2 (ja) 2006-11-10 2007-11-12 微生物およびその部分が誘導する炭水化物特異的細胞性免疫
JP2009535633A Withdrawn JP2010508834A (ja) 2006-11-10 2007-11-12 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015074801A Withdrawn JP2015133979A (ja) 2006-11-10 2015-04-01 微生物およびその部分が誘導する炭水化物特異的細胞性免疫

Country Status (17)

Country Link
US (2) US8592165B2 (https=)
EP (4) EP1920782A1 (https=)
JP (4) JP5771355B2 (https=)
KR (2) KR20150054014A (https=)
CN (1) CN101573138B (https=)
AU (2) AU2007316820B2 (https=)
BR (2) BRPI0718796A2 (https=)
CA (2) CA2668603A1 (https=)
EA (1) EA025395B1 (https=)
ES (1) ES2715045T3 (https=)
IL (2) IL198567A0 (https=)
MX (1) MX2009005004A (https=)
NO (1) NO20091748L (https=)
NZ (1) NZ577559A (https=)
PL (1) PL1920781T3 (https=)
RU (1) RU2460074C2 (https=)
WO (2) WO2008055702A1 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3539981A1 (en) 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
EP2119365B1 (de) 2008-05-13 2017-08-16 Glycotope GmbH Fermentationsprozess
JP2011520435A (ja) * 2008-05-13 2011-07-21 グリコトープ ゲーエムベーハー 発酵プロセス
WO2011017013A2 (en) * 2009-07-27 2011-02-10 The University Of North Carolina At Chapel Hill Enterococcus and fecal bacteroides for rapid water quality assessment
GB2475226A (en) 2009-11-03 2011-05-18 Genetic Analysis As Universal Prokaryote 16S ribosome PCR primer pair
WO2011153226A2 (en) * 2010-06-01 2011-12-08 Moore Research Enterprises Llc Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
EP2646567A4 (en) * 2010-10-04 2014-03-26 British Columbia Cancer Agency DETECTION OF FUSOBACTERIUM IN A GASTROINTESTINAL SAMPLE FOR THE DIAGNOSIS OF GASTROINTESTINAL CARCINOMA
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
RU2014111049A (ru) * 2011-08-22 2015-09-27 Гликотоп Гмбх Микроорганизмы вида bacteroides xylanisolvens
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US9360470B2 (en) * 2012-06-26 2016-06-07 Centre Hospitalier Regional Universitaire De Lille In vitro diagnostic method for an invasive fungal infection using MALDI-TOFF mass spectrometry
CN102813916B (zh) * 2012-09-05 2015-03-11 北京希普生国际生物医学研究院 一种快速获取树突状细胞疫苗的制备方法及其应用
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP2818056A1 (en) * 2013-06-25 2014-12-31 Biosearch S.A. Probiotic bacteria comprising metals, metal nanoparticles and uses thereof
WO2015020765A2 (en) * 2013-08-06 2015-02-12 Trustees Of Dartmouth College Unglycosylated lysostaphin variant protein
CA2941029C (en) 2014-04-10 2021-02-16 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN104546932A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546933A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
EP3400953A1 (en) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
AR103260A1 (es) 2014-12-23 2017-04-26 4D Pharma Res Ltd Modulación inmunitaria
EP4548978A3 (en) 2015-01-29 2025-08-06 Oxyrase, Inc. Methods for inhibiting tumor growth
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
NZ737752A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
ME03487B (me) 2016-03-04 2020-01-20 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP4548925A3 (en) 2016-07-01 2025-07-09 Infinant Health, Inc Method for facilitating maturation of the mammalian immune system
TWI802545B (zh) 2016-07-13 2023-05-21 英商4D製藥有限公司 包含細菌菌株之組合物
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
CA3066189A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
WO2019217951A1 (en) * 2018-05-11 2019-11-14 Obi Pharma Inc. Method for predicting human immune response
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
EP3999637B1 (en) * 2019-07-18 2025-04-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
IL295306A (en) * 2020-02-03 2022-10-01 Technion Res & Dev Foundation Method for isolating a microorganism
CN115992084A (zh) * 2022-08-18 2023-04-21 吉林农业大学 表达牛巨噬细胞粒细胞集落刺激因子的重组乳酸菌及应用
WO2026078981A1 (ja) * 2024-10-08 2026-04-16 キリンホールディングス株式会社 免疫賦活能を有する細菌及びそれを含有する組成物
JP7838165B1 (ja) * 2024-10-08 2026-03-31 キリンホールディングス株式会社 免疫賦活能を有する細菌及びそれを含有する組成物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4672316A (en) 1983-08-19 1987-06-09 Werkzeugmaschinenfabrik Oerlikon-Buhrle Ag Method for calibrating a muzzle velocity measuring device
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) * 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
CA2100671C (en) 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
JP3698370B2 (ja) 1992-04-13 2005-09-21 ダナ−ファーバー キャンサー インスティチュート インク 癌腫抗原用抗体
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
US7137011B1 (en) * 1993-09-01 2006-11-14 Sandisk Corporation Removable mother/daughter peripheral card
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
JP2660175B2 (ja) * 1994-10-19 1997-10-08 北海道 キクイモ由来のレクチンおよびその分離精製法
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US5939404A (en) * 1995-12-27 1999-08-17 Ngk Insulators, Ltd. Cancer metastasis inhibitor containing a streptococcus agalactiae Ia type or Ib type surface polysaccharide as a main ingredient
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
ATE550042T1 (de) * 1997-11-20 2012-04-15 Vical Inc Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
JP4437192B2 (ja) * 1998-02-20 2010-03-24 タノックス インコーポレイテッド 補体活性化阻害剤
JP2000028599A (ja) * 1998-04-15 2000-01-28 Ebara Corp D―マンノ―ス識別アフィニティ―担体とその使用方法
EP1399538A4 (en) 1999-03-02 2004-03-24 Human Genome Sciences Inc TECHOLOGICAL MANIPULATION OF INTRACELLULAR SIALIZATION PATHS
CA2368734C (en) 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
AU7743100A (en) * 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
JP2004534088A (ja) * 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
AU2002336981A1 (en) 2001-08-17 2003-03-03 Charite Glycoconjugates of sialic acid derivates, methods for their production and use thereof
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
CN1201817C (zh) * 2001-11-09 2005-05-18 北京大学肝病研究所 一种治疗肝癌的肿瘤ct抗原免疫诱导剂及其制备方法
EP1451217A4 (en) * 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
ES2524442T3 (es) 2002-07-22 2014-12-09 Glycotope Gmbh Procedimiento para la producción de una mucina (MUC1) inmunoestimulante
DK1530628T3 (da) * 2002-08-16 2011-01-10 Glycotope Gmbh Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser
US20060095978A1 (en) * 2002-09-26 2006-05-04 Christoph Burkhart Screening assay
DE10256900A1 (de) * 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
RU2364625C2 (ru) * 2003-02-27 2009-08-20 Норсуэст Байотерапьютикс, Инк. Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов
GB0315991D0 (en) * 2003-07-08 2003-08-13 Dakocytomation Denmark As Standard
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
CN103627670B (zh) * 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
JP2008505130A (ja) * 2004-07-01 2008-02-21 ケベンハウンス・ウニヴェルジテート レプトスピラ属感染の治療による多発性硬化症の治療及び予防方法
JP4904266B2 (ja) * 2004-07-26 2012-03-28 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗−tf−抗原抗体の治療的使用
US9066483B2 (en) * 2005-08-01 2015-06-30 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Low fiber yellow canola seeds comprising high, oleic, low linolenic oil
EP3539981A1 (en) * 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
JP2011520435A (ja) * 2008-05-13 2011-07-21 グリコトープ ゲーエムベーハー 発酵プロセス
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
ES2686313T3 (es) * 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral

Similar Documents

Publication Publication Date Title
JP2015134813A5 (https=)
JP2010508834A5 (https=)
US12350298B2 (en) Microbiome related immunotherapies
JP6662775B2 (ja) 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター(プレ、プロ又はシンバイオティクス)の使用
US8007785B2 (en) Method for treating colon cancer with tumour-reactive T-lymphocytes
JP2025183317A (ja) Nk細胞を活性化するための組成物及び方法
KR102833272B1 (ko) 변형된 효모-브라큐리 면역치료학적 조성물
JP2015520129A (ja) 多価乳がんワクチン
Zhou et al. Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy
Chablani et al. Formulation and evaluation of a particulate oral breast cancer vaccine
US20250235518A1 (en) Method for preparing tumor vaccine using magnetic thermal inactivation technology
JP7040701B2 (ja) 抗がん腫瘍溶解性ウイルス併用療法および優良レスポンダー選択プラットフォーム
Norimatsu et al. Live Salmonella enterica serovar Typhimurium (S. Typhimurium) elicit dendritic cell responses that differ from those induced by killed S. Typhimurium
Hulikova et al. N-acetyl-D-glucosamine-coated polyamidoamine dendrimer promotes tumor-specific B cell responses via natural killer cell activation
Calderon-Gonzalez et al. Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma
TWI674108B (zh) 索脊瘤之以酵母菌爲基礎之免疫療法
AU2020414040A1 (en) Cancer treatment method and medicine
JP4840858B2 (ja) 癌ワクチン
JP4840866B2 (ja) 癌ワクチン
Cordero et al. Immunology and Immunotherapy of Colorectal Cancer
JP7655581B1 (ja) 免疫チェックポイント阻害サプリメント
Fang et al. potential target for radioimmunotherapy in
Zhu et al. Administration of MIP-3α gene to the tumor following radiation therapy boosts anti-tumor immunity in a murine model of lung carcinoma
Jiang et al. Vaccination with synthetic long peptide and CpG 2395 in AddaVax induces potent anti-tumor effects
WO2026074164A1 (en) Methods and compositions for treating cancer